Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

9
Dispensing disruption: Are pharmacies ready for digital rivals?

2018-07-06 theage.com.au
When Amazon announced its purchase last week of online pharmacy PillPack, which packages and delivers pre-sorted doses of prescribed drugs direct to consumers’ homes, major US-based pharmacies from CVS Health to Walgreens saw their share prices fall about 10 per cent.
EBOSF RMYHY API RHC EBOSY CVS EBO RMSYF EBO

9
Dispensing disruption: Are pharmacies ready for digital rivals?

2018-07-06 smh.com.au
When Amazon announced its purchase last week of online pharmacy PillPack, which packages and delivers pre-sorted doses of prescribed drugs direct to consumers’ homes, major US-based pharmacies from CVS Health to Walgreens saw their share prices fall about 10 per cent.
EBOSF RMYHY API RHC EBOSY CVS EBO RMSYF EBO

0
ASX lifts for the week despite the looming trade war

2018-07-06 theage.com.au
The Australian sharemarket has ended the week with a fresh 10-1/2-year high on Friday, despite the US going ahead with tariffs that could potentially begin an all-out trade war with China.
DB API EBOSY MS.PRE MS.PRF MS.PRG MS.PRA EBO RSG EBOSF MS.PRI RMGGY MS.PRK RMGGF MS EBO

0
ASX lifts for the week despite the looming trade war

2018-07-06 smh.com.au
The Australian sharemarket has ended the week with a fresh 10-1/2-year high on Friday, despite the US going ahead with tariffs that could potentially begin an all-out trade war with China.
DB API EBOSY MS.PRE MS.PRF MS.PRG MS.PRA EBO RSG EBOSF MS.PRI RMGGY MS.PRK RMGGF MS EBO

0
NZ shares up; Auckland Airport leads gains

2018-07-05 nzherald.co.nz
New Zealand shares rose in light trading, led higher by Auckland International Airport and Westpac Banking Corp, with Heartland Bank and Fletcher Building softening.
AIA FBU WBC FCREY EBOSY WEBNF WBK ACKDF FRCEF EBO AUKNY EBOSF AIA WBC FBU SKLUY SKL EBO

2
Australian shares advance on strength of major banks

2018-07-03 theage.com.au
The Australian sharemarket has recorded only its second advance in the last eight sessions despite a broad retreat of commodity prices overnight.
PILBF RIO DB BLT RIO IAG MS.PRE MS.PRF MS.PRG MS.PRA BEPTF RTPPF GALXF RTNTF MS TWE SML IAUGY PLS TSRYY BHPBF EBOSY EBO BCHEY BPT EBOSF TSRYF GXY IAUGF MS.PRI BHP RIO MS.PRK BBL BHP BHPLF EBO

2
Australian shares advance on strength of major banks

2018-07-03 smh.com.au
The Australian sharemarket has recorded only its second advance in the last eight sessions despite a broad retreat of commodity prices overnight.
PILBF RIO DB BLT RIO IAG MS.PRE MS.PRF MS.PRG MS.PRA BEPTF RTPPF GALXF RTNTF MS TWE SML IAUGY PLS TSRYY BHPBF EBOSY EBO BCHEY BPT EBOSF TSRYF GXY IAUGF MS.PRI BHP RIO MS.PRK BBL BHP BHPLF EBO

0
NZX 50 rises 1.2% to new record on Ebos Group gains

2018-07-03 nzherald.co.nz
New Zealand shares jumped to a record with Ebos Group hitting a fresh high while A2 Milk Co and Synlait Milk gained on news they plan to extend their supply contract.
EBOSF NZTCY SPKKY OHE EBOSY SPK NZTCF EBO FTRRF EBO SML

2
Sigma told to 'lick wounds' after Chemist Warehouse hammering

2018-07-02 theage.com.au
Sigma Healthcare's largest investor says the company should take time to lick its wounds rather than rush into new investments, after the loss of its biggest contract cut it projected earnings in half and sent its share price plunging 40 per cent in a single day.
EBOSF EBOSY EBO EBO

2
Sigma told to 'lick wounds' after Chemist Warehouse hammering

2018-07-02 smh.com.au
Sigma Healthcare's largest investor says the company should take time to lick its wounds rather than rush into new investments, after the loss of its biggest contract cut it projected earnings in half and sent its share price plunging 40 per cent in a single day.
EBOSF EBOSY EBO EBO

2
MARKET WRAP: Ebos deal dominates otherwise subdued sharemarket

2018-07-02 nbr.co.nz
Harbour Asset Management analyst Shane Solly says global markets could remain volatile due to US tariffs.
EBOSF EBOSY GTK EBO EBO

2
Sigma shares plunge on loss of Chemist Warehouse contract

2018-07-02 theage.com.au
Sigma Healthcare's shares have plunged more than 45 per cent to seven-year lows after the pharmacy operator failed to extend a pharmaceutical supply contract with Chemist Warehouse and said it would have to cut costs to survive.
EBOSF EBOSY EBO EBO

2
Sigma shares plunge on loss of Chemist Warehouse contract

2018-07-02 smh.com.au
Sigma Healthcare's shares have plunged more than 45 per cent to seven-year lows after the pharmacy operator failed to extend a pharmaceutical supply contract with Chemist Warehouse and said it would have to cut costs to survive.
EBOSF EBOSY EBO EBO

26
NZ shares taper off in strong June quarter

2018-06-29 nzherald.co.nz
New Zealand shares ran out of puff in the final day of the June quarter, which has been the strongest quarterly performance in more than two years. Summerset Group Holdings and Ebos Group declined and Westpac Banking Corp gained.
SGM FCREY NZTCF SMSMY ACKDF AUKNY FTRRF KMD SMUPF AOTUF SNZ KMD SML KTHDY AIA FBU WBC SCY SPKKY NZTCY EBOSY SPK WEBNF WBK FRCEF EBO EBOSF AIA WBC FBU EBO

27
Shares fall as global tensions keep investors on the sidelines

2018-04-16 nzherald.co.nz
New Zealand shares fell in relatively subdued trading, led by Ebos Group, Ryman Healthcare, Air New Zealand and Fletcher Building. Comvita fell after a profit warning while A2 Milk gained on news of a deal in South Korea.
FBU RHCGF AIR FCREY SPKKY EBOSY NZTCY SPK NZTCF RYM FRCEF ANZFY EBO AIZ EBOSF SKC FBU ANZLY RYHTY ANZFF EBO SML

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to NZX:EBO / Ebos Group on message board site Silicon Investor.

Music Jukebox Facebook, Inc.
If I knew Facebook Scandal ahead.... Ebola Outbreak 2014 - News, Updates and Related Investments
Facebook Gems u0026 Delights Conseco (CNO) Reborn
FACEBOOK IPO Facebook Sympathy Plays
LITEBOX?? What Stocks will rebound in 2009??